Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association - 1 Sept 2018

Salvi Fabrizio, Volpe Roberto, Pastorelli Francesca, Bianchi Andrea, Vella Alessandra, Rapezzi Claudio, Mascalchi Mario

Abstract excerpt

Oculomeningovascular amyloidosis is a variant of transthyretin (TTR) amyloidotic polyneuropathy, which is associated with blindness and brain ischemia, microhemorrages, and siderosis due to prominent production of the abnormal TTR in the eye and in the choroid plexuses. Tafamidis is a TTR stabilizer that is orally administered and, by interfering with amyloid fibril formation and deposition, is capable of slowing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Neuropathies, Familial
Share to Blindness

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Ischemia

Share to Cerebrovascular Disorders

Share to Eye Diseases

Share to Intracranial Hemorrhages

Share to Prealbumin

Share to Treatment Failure

Source

Identifiers

PMID: 29779881
DOI: 10.1016/j.jstrokecerebrovasdis.2018.04.033

Genes

TTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.PMID 29779881Read ↗

Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients.Semantic proximity Read ↗

Tafamidis for transthyretin amyloidosis.Semantic proximity Read ↗

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.Semantic proximity Read ↗

Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.Semantic proximity Read ↗

Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.Semantic proximity Read ↗

Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.Semantic proximity Read ↗

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.Semantic proximity Read ↗

A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.Semantic proximity Read ↗

Tafamidis (Vyndaqel): a light for FAP patients.Semantic proximity Read ↗

Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.Semantic proximity Read ↗

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.Semantic proximity Read ↗

TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.